<DOC>
	<DOCNO>NCT00439127</DOCNO>
	<brief_summary>Thyroidectomy follow administration large activity 131-iodine ( 131I ) treatment choice differentiate thyroid carcinoma ( DTC ) . The serum thyroglobulin ( Tg ) measurement hypothyroidism ( offT4-Tg ) , radioiodine thyroid ablation , prove effective predict persistent/recurrent disease . However , Tg measurement use correspond value preablative offT4-Tg rhTSH use stimulous treatment . The present study undertaken evaluate post-thyroidectomy Tg value , measure rhTSH-stimulation radioiodine administration , prognostic value patient affect DTC . We enrol 28 patient DTC submit total thyroidectomy . Thyroxine ( T4 ) treatment start surgery suppress TSH level . Six nine week later Tg level measure basally ( onT4-Tg ) rhTSH ( rhTSH-Tg ) stimulation . Subsequently , T4 stop serum Tg measure ( offT4-Tg ) 3700 MBq 131I-iodide administration . A post-treatment whole body scan ( PT-WBS ) perform neck radioiodine uptake ( RAIU ) measure . A significant relationship find onT4-Tg rhTSH-Tg offT4-Tg . The onT4-Tg level 0.2 ng/mL high predict PT-WBS result 100 % negative 43 % positive predictive value , respectively . Additionally onT4-Tg level 0.9 ng/mL predicts 12-months recurrence 100 % negative 60 % positive predictive value . In comparison , 1.0 ng/mL high offT4-Tg value predict PT-WBS result 12-months restaging 94 % 100 % negative 45 % 27 % positive predictive value , respectively . Basing data conclude preablative onT4-Tg may value prognostic marker rhTSH-aided radioiodine ablation do . Additionally , role preblative onT4-Tg measurement yard-stick radioiodine ablation evaluate .</brief_summary>
	<brief_title>OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation</brief_title>
	<detailed_description>Introduction Total ( near-total ) thyroidectomy follow TSH-stimulated administration large activity 131-iodine ( 131I ) treatment choice DTC [ 1-3 ] . The serum thyroglobulin ( Tg ) measurement hypothyroidism , radioiodine thyroid ablation , prove effective predict persistent/recurrent disease [ 4-8 ] . Recently recombinant human TSH ( rhTSH ) show safely employ instead thyroxine ( T4 ) withdrawal ( offT4 ) prepare patient radioiodine ablation [ 9-10 ] . However , Tg level measure 48 hour radioiodine administration rhTSH use stimulation [ 11 ] . Consequently , due radioiodine-induced thyroid cell damage Tg release , Tg measurement would reliable predictive value patient treat rhTSH stimulation [ 12 ] . The present study undertaken evaluate preablativeTg measurement T4 treatment prognostic value serve surrogate marker offT4-stimulated preablative Tg . Patients method Patients selection We retrospectively enrol 28 consecutive patient affect histologically prove DTC ( 23 papillary , 5 follicular ) submit total thyroidectomy central compartment lymph-node dissection . Thyroxine ( T4 ) treatment start immediately surgery suppress TSH level . Six nine week later Tg level measure basally ( onT4-Tg ) rhTSH ( rhTSH-Tg ) stimulation previously describe [ 13 ] . Subsequently , T4 stop 4 week serum Tg measure ( offT4-Tg ) 3700 MBq 131I-iodide administration . A post-treatment whole body scan ( PT-WBS ) radioiodine uptake ( RAIU ) calculation perform accord previously describe protocol [ 1 ] . All non physiologic iodine uptake area thyroid bed consider positive finding [ 14 , 15 ] . Patients positive PT-WBS underwent specific treatment personalized follow-up . Patients negative PT-WBS immediately restart T4 suppressive treatment . Final restaging perform patient 12 month last treatment neck ultrasound , onT4-Tg assay offT4-diagnostic WBS ( DgWBS ) Tg assay ( 4 week T4 withdrawal ; require TSH &gt; 30 mUI/L ) . Clinical pathological characteristic select patient summarize Table 1 . Serum Tg assay screen interference Serum Tg assay duplicate specific high-sensitive IRMA assay ( DYNOtest® Tg-plus , BRAHMS Diagnostica GmbH , Berlin , Germany ) accord producer ’ instruction . This method provide sensitivity 0.05 ng/mL functional sensitivity 0.2 ng/mL [ 16 , 17 ] . As previously publish , preablative offT4 serum Tg value 4.5 ng/mL 3.2 ng/mL consider positive respect PT-WBS 12 month restaging result , respectively [ 8 ] . Otherwise , offT4-Tg value higher 0.2 ng/ml measure 12 month thyroid ablation consider positive persisting/relapsing disease . [ 18 , 19 ] . The presence anti-thyroglobulin antibody ( AbTg ) screen specific radioimmunoassay ( DYNOtest® anti-TGn , BRAHMS Diagnostica GmbH , Berlin , Germany ) recovery test specific Tg-recovery buffer provide producer . Sera show AbTg level 60 U/mL and/or recover less 80 % 120 % exclude study . Quality control ensure assay two level control serum series , re-assessing serum show coefficient variation exceed 10 % bimonthly partecipation European inter-laboratory control OncocheckTM . Statistics Quantitative data express mean ± SD . Differences group assess two-tailed unpaired t-test . The relationship variable assess linear regression analysis . In order allow statistical analysis value undetectable serum Tg express &lt; 0.2 ng/nL arbitrarily change 0.10 ng/mL . Statistical significance define p-value &lt; 0.05 . Ethics All diagnostic therapeutic procedure perform accord regulation local ethic committee . Informed consensus obtain patient . Results The overall result summarize Table I . Relationship Between Post-surgery onT4-Tg , rhTSH-Tg offT4-Tg A significant positive relationship find onT4-Tg rhTSH-Tg ( p &lt; .0001 ) offT4-Tg ( p &lt; 0.0001 ) ( Figure 1 , A-B-C ) well rhTSH offT4-stimulated Tg ( p &lt; .0001 ) . Relationship Between Post-surgery Serum Tg Thyroid Remnant Radioiodine Uptake ( RAIU ) Among 22 patient show DTC metastasis PT-WBS serum distribution onT4-Tg , rhTSH-Tg offT4-Tg 0.342±0.402 ; 0.664±0.803 1.195±1.485 ng/mL respectively . Both rhTSH offT4-stimulated Tg level relate RAIU ( p &lt; .05 &lt; .005 , respectively ) significant relationship find RAIU onT4-Tg level ( Figure 1 , D-E-F ) . Relationship Between Post-surgery Serum Tg PT-WBS result The patient positive PT-WBS show high onT4-Tg ( 0.617±0.445 vs 0.341±0.402 ng/mL ) , rhTSH-Tg ( 2.150±1.249 vs 0.664±0.803 ng/mL ) offT4-Tg ( 4.417±2.136 vs 1.195±1.485 ng/mL ) level compare patient negative scan . Among 14 patient undetectable onT4-Tg ( i.e . ≤0.2 ng/mL ) none positive PT-WBS neither recurrence 12-months restaging . Additionally , none patient show stimulated Tg value 0.4 ng/mL 1.0 ng/mL rhTSH stimulation T4 withdrawal , respectively . Viceversa , among 14 patient onT4-Tg level 0.2 ng/mL , 6 positive PT-WBS ( onT4-Tg : 0.3 1.4 ng/mL ) 3 show DTC recurrence 12 month restaging ( onT4-Tg : 0.9 1.7 ng/mL ) . Consequently , onT4-Tg level predict PT-WBS result 100 % negative 43 % positive predictive value , respectively . Additionally onT4-Tg level 0.9 ng/mL predicts 12-months recurrence 100 % negative 60 % positive predictive value . In comparison , 1.0 ng/mL high offT4-Tg value predict PT-WBS result 12-months restaging 94 % 100 % negative 45 % 27 % positive predictive value , respectively . Discussion Many report indicate usefulness Tg concentration measurement radioiodine treatment early detection DTC relapse metastasis [ 4-8 , 20 , 21 ] . Three factor determine Tg concentration clinical situation : thyroid cell mass , thyroid cell damage activation TSH receptor [ 22 ] . When Tg measure radioiodine ablation effect surgical damage generally vanish endogenous TSH level increase patient : consequently thyroid remnant mass major determinant serum Tg concentration [ 23 ] . However , rhTSH-stimulated Tg use instead preablative offT4-Tg rhTSH employ prepare radioiodine ablation [ 12 ] . Therefore evaluated role post-surgery onT4-Tg surrogate prognostic marker . We choiced suppress TSH level order normalize effect TSH stimulation thyroid remnant . Clearly , TSH suppression reduce Tg level : however , high-sensitive Tg assay provide good distinction lower limit euthyroid reference range functional sensitivity limit detect small amount thyroid tissue even TSH-suppressed state ( 22 , 23 ) . We show significant positive relationship post-surgery Tg measure T4 treatment TSH stimulation . No relationship find RAIU ( i.e . expression remnant mass ) onT4-Tg , probably due cluster Tg level low 0.2 ng/mL ( see statistic paragraph ) . However , undetectable onT4-Tg surgery identifies patient free metastasis PT-WBS without late recurreces early 12-months follow-up . None patient show significant increase rhTSH offT4-stimulated Tg radioiodine ablation . This seem indicate relationship Tg expression thyroid tissue mass manteined even TSH suppression state : Therefore undetectable serum onT4-Tg really identify patient without significant thyroid tissue amount well stimulate Tg . All patient perform extracapsular total thyroidectomy dedicate thyroid surgery unit thyroid remnant , express RAIU , low series others . This mean data directly translate patient treat limited surgery . Globally , base data conclude preablative onT4-Tg may value prognostic marker rhTSH-aided radioiodine ablation do . Additionally , role preblative onT4-Tg measurement yard-stick radioiodine ablation evaluate . References 1 . Schlumberger MJ . Medical progress : papillary follicular thyroid carcinoma . N Engl J Med 1998 ; 338 : 297-306 . 2 . Pacini F. Follow-up differentiate thyroid cancer . Eur J Nucl Med 2002 ; 29 ( S2 ) : 492-6 . 3 . Klain M , Richard M , Leboulleux S et al . Radioiodine therapy papillary follicular thyroid carcinoma . Eur J Nucl Med 2002 ; 29 ( S2 ) : S479-85 . 4 . Ronga G , Filesi M , Ventroni G et al . Value first serum thyroglobulin level total thyroidectomy diagnosis metastasis differentiate thyroid carcinoma . Eur J Nucl Med 1999 ; 26 ( 11 ) : 1448-52 . 5 . Grünwald F , Menzel C , Fimmers R et al . Prognostic value thyroglobulin thyroidectomy ablative radioiodine therapy thyroid cancer . J Nucl Med 1996 ; 37 ( 12 ) : 1962-4 . 6 . Lin JD , Huang MJ , Hsu BR , Chao TC , Hsueh C , Liu FH et al . Significance postoperative serum thyroglobulin level patient papillary follicular thyroid carcinoma . J Surg Oncol 2002 ; 80 : 45-51 . 7 . Kim TY , Kim WB , Kim ES , Ryu JS , Yeo JS , Kim SC et al . Serum thyroglobulin level time 131I remnant ablation thyroidectomy useful early prediction clinical recurrence low-risk patient differentiate thyroid carcinoma . J Clin Endocrinol Metab 2005 ; 90 : 1440-5 . 8 . Giovanella L , Ceriani L , Ghelfo A , Keller F. Thyroglobulin assay 4 week thyroidectomy predict outcome low-risk papillary thyroid carcinoma.Clin Chem Lab Med 2005 ; 43 : 843-7 . 9 . Barbaro D , Boni G , Meucci G , Simi U , Lapi P , Orsini P et al . Recombinant human thyroid-stimulating hormone effective radioiodine ablation post-surgical thyroid remnant . Nucl Med Commun . 2006 ; 27 ( 8 ) :627-32 . 10 . Pacini F , Ladenson PW , Schlumberger M , Driedger A , Luster M , Kloos RT et al . Radioiodine ablation thyroid remnant preparation recombinant human thyrotropin differentiate thyroid carcinoma : result international , randomize , control study . J Clin Endocrinol Metab . 2006 ; 91 : 926-32 . 11 . Robbins RJ , Svrivastava S , Shaha A , Ghossein R , Larson SM , Fleischer M et al . Factors influence basal recombinant human thyrotropin-stimulated serum thyroglobulin patient metastatic thyroid carcinoma . J Clin Endocrinol Metab . 2004 ; 89 : 6010-6 . 12 . Taieb D , Lussato D , Guedj E , Roux F , Mundler O . Early sequential change serum thyroglobulin radioiodine ablation thyroid cancer : possible clinical implication recombinant human thyrotropin-aided therapy . Thyroid 2006 ; 16 : 177-9 . 13 . Mazzaferri E , Robbins RJ , Spencer CA , Braverman LE , Pacini F , Wartofsky L et al . A consensus report role serum thyroglobulin monitor method low-risk patient papillary thyroid carcinoma . J Clin Endocrinol Metab 2003 ; 88 : 1433-41 . 14 . Giovanella L , Ceriani L , Ghelfo A , Keller F , Sacchi A , Maffioli M et al . Thyroglobulin assay thyroxine treatment low-risk differentiated thyroid cancer management : comparison recombinant human thyrotropin-stimulated assay imaging procedure . Clin Chem Lab Med 2006 ; 44:248-52 . 15 . Reiners C , Luster M , Lassman M. Clinical experience recombinant human thyroid-stimulating hormone ( rhTSH ) : whole-body scan iodine-131 . J Endocrinol Invest 1999 ; 22 ( S11 ) :17-24 . 16 . Giovanella L , Ceriani . High-sensitivity human thyroglobulin ( hTG ) immunoradiometric assay follow-up patient differentiate thyroid carcinoma . Clin Chem Lab Med 2002 ; 40 ( 5 ) : 480-4 . 17 . Morghentaler NG , Froelich J , Rendl J , Willnich M , Alonso C , Bergmann A et al . Technical evaluation new immunoradiometric new immunoluminometric assay thyroglobulin . Clin Chem 2002 ; 48 ( 7 ) : 1077-83 . 18 . Iervasi A , Iervasi G , Carpi A , Zucchelli GC . Serum thyroglobulin measurement : clinical background main methodological aspect clinical impact . Biomed Pharmacother . 2006 ; 60 : 414-24 19 . Sahlmann CO , Schreivogel I , Angerstein C et al . Clinical evaluation new thyroglobulin immunoradiometric assay follow-up differentiate thyroid carcinoma . Nuklearmedizin 2003 ; 42 : 71-7 . 20 . Makarewicz J , Adamczewski Z , Knapska-Kucharska M , Lewinski A . Evaluation diagnostic value first thyroglobulin determination detect metastasis differentiate thyroid carcinoma surgery . Exp Clin Endocrinol Diabetes 2006 ; 114 : 485-9 . 21. de Rosario PW , Guinaraes VC , Maia FF , Fagundes TA , Purisch S , Padrao EL et al . Thyroglobulin ablation correlation posttreatment scan . Laryngoscope 2005 ; 115 : 264-7 . 22 . Spencer CA , LoPresti JS , Fatemi S , Nicoloff JT . Detection residual recurrent differentiate thyroid carcinoma serum thyroglobulin measurement . Thyroid 1999 ; 9 : 435-41 . 23 . Wunderlich G , Zophel K , Crook L , Smith S , Smith BR , Franke WG . A high-sensitivity enzyme-linked immunosorbent assay serum thyroglobulin . Thyroid 2001 ; 11 : 819-24 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>Hiostologically prove DTC ( M0 ) Preoperative metastasis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>thyroglobulin</keyword>
	<keyword>thyroid carcinoma</keyword>
	<keyword>tumour marker</keyword>
	<keyword>radioiodine</keyword>
	<keyword>recombinant human TSH</keyword>
</DOC>